0932 ET - Eli Lilly is slightly higher is early trading after another blowout quarter driven by GLP-1 drugs. 4Q revenue rises 45% to $13.53 billion. Revenue from new products climbs by $3.15 billion to $5.64 billion, driven Zepbound and Mounjaro. Lilly's fortunes echo those of Danish rival Novo Nordisk, which sold$4.71 billion of its Ozempic drug in 4Q. Lilly shares have more than quintupled in the last five years. Rival drug makers, such as Novartis, have admitted hunting for obesity drugs of their own. Lilly and Novo have major first-mover advantage, with smaller players such as Viking Therapeutics still playing catchup. Anya Schiess, a partner at JPMorgan's asset management unit, is among those who have predicted GLP-1s will be the best-selling class of drugs yet. (rob.curran@dowjones.com)
(END) Dow Jones Newswires
February 06, 2025 09:32 ET (14:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。